Laden…
Ibogaine is a psychoactive indole alkaloid, primarily known for its potential anti-addictive properties. It acts complexly across multiple neurotransmitter systems, including serotonin, dopamine, and NMDA receptors. Due to its strong effects and possible cardiotoxic effects, its use is classified as risky. Ibogaine is traditionally used in West African cultures and is gaining scientific interest in the context of addiction therapy.
Class
Psychedelika
Pharmacological context
Mechanism
Ibogaine primarily acts as an agonist at the 5-HT2A receptor and as an...
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
Interpret risks carefully
Condensed from structured notes
Translation in progress
The German version has more complete content. This English page is being expanded; safety-critical risk and interaction sections may still appear while translation continues.
Receptor Targets
Mechanism of Action
Designations
IUPAC: Ibogaine
Receptor Profile
Der NMDA-Rezeptor ist ein ionotroper Glutamatrezeptor, der eine zentrale Rolle bei synaptischer Plastizität, Lernen und Gedächtnisbildung spielt. Er benötigt sowohl Glutamat als auch Glycin als Co-Agonisten zur Aktivierung.
Der 5-HT2A-Rezeptor ist ein Serotonin-Rezeptor der Klasse Gq-gekoppelter GPCRs. Er ist der primäre molekulare Angriffspunkt klassischer Psychedelika und spielt eine Rolle bei Kognition und Wahrnehmung.
Der Dopamintransporter (DAT) ist ein Natrium-abhängiger Monoamintransporter, der Dopamin aus dem synaptischen Spalt entfernt. Er ist ein zentrales Ziel von Stimulants und spielt eine Schlüsselrolle im Belohnungssystem.
Substance Fingerprint
Pharmacological profile based on receptor binding, mechanism of action, and substance class. Limited data — interpret profile with caution.
Synapedia Evidence
Effects & Pharmacology is partially translated. Some details are still being expanded.
Ibogaine primarily acts as an agonist at the 5-HT2A receptor and as an antagonist at the NMDA receptor. These interactions influence the serotonergic and glutamatergic systems, leading to its psychoactive effects.
Known Effects
Individual effects may vary significantly. These are pharmacologically documented effects.
Reported range 10–20 mg
Total duration 8–12 hours
Oral
| Tier | Dosage |
|---|---|
| Light | 5–10 mg |
| Reported | 10–20 mg |
| Strong | 20–30 mg |
Oral
Onset
1–2 hours
Peak
2–4 hours
Total duration
8–12 hours
After effects
1–2 days
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks & Harm Reduction is partially translated. Some details are still being expanded.
Risks
Summary
Mögliche kardiotoxische Effekte, insbesondere bei hohen Dosen oder bestehenden Herzproblemen.
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.